Special Diversified Opportunities Inc. (SDOI) insider have most recently took part in a trading activity. On Dec 15, 2017 Standard General L.p., 10% Owner bought 3,653 shares having total worth of $39,087 at the price of $10.7 per share, following the transaction a total of 7,260,075 shares owned by Standard General L.p.. Before this latest buy, Standard General L.p. purchased SDOI at 3 other times during the past twelve months, for a total investment of $360,879 at an average of $9.9 per share.
The stock has experienced a total of 3 insider trades in the past three months. These trades include 3 buy trades. Furthermore, over the past 12 months , the stock was traded 4 times by insiders. an employee of the company was the buyer in 4 instances.
|Time Frame||Number of Insider Buy||Number of Insider Sell||Stock Price Change(%)|
Shares of Special Diversified Opportunities Inc. (SDOI) traded up 4.07% on May 30, 2017, hitting $0.87. 1,795 shares of the company’s stock traded hands. Special Diversified Opportunities Inc. has a 52 week low of $0.74 and a 52 week high of $1.13. The company’s market cap is $0 million.
Strategic Diagnostics, Inc., is a Delaware corporation formed in 1990. It is a biotechnology company which develops, commercializes and markets products and solutions that preserve and enhance the quality of human health and wellness. It is a provider of a range of life sciences products and services, including custom antibodies, in-vitro diagnostic-grade antibodies, proprietary critical reagent products, associated bio-processing services, and custom assay design and development services. The Company’s products and services are sold to, and often incorporated in the production process for other commercial products used by a range of customers including pharmaceutical, biotechnology and diagnostic companies, and major biomedical research centers both domestically and internationally. The Company produces antibodies to targets and biomarkers of interest allowing customers to quickly assess the feasibility, efficacy and safety of compounds in their developmental pipelines. The Company’s main business activities are in two areas, Life Sciences Research Antibodies and Assay Development and In vitro Diagnostic antibody reagents. The Company has substantial resources towards the development of its proprietary Genomic Antibody Technology (‘GAT’) program, with the intent of making this program a key element of the Company’s Life Sciences strategy for establishing and maintaining sustainable differentiation in key markets. GAT was developed to address this growing need for high quality reagents. The Company’s main competitors include Covance (public), Harlan (private), Lampire (private), HyTest (private) and Scantibodies (private).
Latest posts by William White (see all)
- Insider Trading Review: FS Investment Corporation $FSIC - January 13, 2018
- Insider Trader Watch: ENERTOPIA CORP $ENRT - January 13, 2018
- Insider Trading in Focus: Swiss Helvetia Fund, Inc. (The) $SWZ - January 13, 2018